The study of the efficacy of late intensification therapy and biochemical markers for pediatric Langerhans cell histiocytosis (JLSG-02)

The study of the efficacy of late intensification therapy and biochemical markers for pediatric Langerhans cell histiocytosis (JLSG-02) - JLSG-02

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018426

Enrollment

150

Registered

2015-07-26

Start date

2002-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhans cell histiocytosis

Interventions

Multiple bone and Multi-system type: Induction A (6 weeks)Patients who had response to Induction A (GR / PR): Early maintenance A (24 weeks) and Late maintenance C (24 weeks) Multiple bone and Multi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with histologicaly diagnosed LCH 2. Patients with Multiple bone or Multi-system type LCH

Exclusion criteria

Exclusion criteria: 1. Patients with organ failure which make difficult to carry out the treatment 2. Patients receiving other treatment except steroids or surgical treatment for LCH 3. Informed consent is not obtained from patients and / or the guardians for treatment JLSG-02

Design outcomes

Primary

Measure	Time frame
Event free survival at 5 years.	—

Secondary

Measure	Time frame
Overall survival at 5 years.	—

Countries

Japan

Contacts

Public ContactAkira Morimoto

Jichi Medical University Pediatrics

info@jlsg.jp0285-44-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026